Who are we?
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnwesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief—and the core of our strategy—is that innovative, highly
differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Drugs Disributed by Amgen Europe B.V
Recombinant Human Erythropoietin. Darbepoetin Alfa 10, 20, 30, 40, 50, 60, 80, 100, 150, 300, 500 mcg. PREFILL. SYRINGES (for single use only,
with/out automat. needle guard): 4 x 10
μg; 20 μg; 30 μg; 40 μg; 50 μg; 60 μg; 80
μg; 100 μg, 150 μg; 1 x 300 μg, 500 μg.
For I.V. and S.C. admin. Similar efficacy
in I.V. and S.C. admin.
PREFILL. PEN (SureClick) (single use
only): 1 x 20 μg, 40 μg, 60 μg, 80 μg, 100
μg,150 μg, 300 μg, 500 μg. S.C. admin
Tmt. anem. assoc. with chron. ren. fail. in
adults and pediatric subjects 11 yrs of
age and over. Aranesp 150, 300, 500 -
also tmt. anem. in adult cancer pts. with
non-myeloid malignancies receiv.
Monoclonal Antibody. Blinatumomab 12.5 mcg/ml. VIAL(concent. for sol. for infus.+ stabilizer sol. for infus.): 1×35mcg. Recommended dose (for adult patients at least 45 kg in weight): 1st Cycle Start. dose Days 1 – 7: 9 mcg/d via cont. infus. Subseq. dose Days 8 – 28: 28 mcg/d via cont. infus. 2 week-tmt. free interval (Days 29 – 42). 2nd cycle & subseq. cycles (Days 1 – 28): 28 mcg/d via cont. infus. See lit.
Tmt. of adult pt. with Philadelphia chromosome-negat. relapsed/ refract.B‑cell precursor ALL. Limitations of use: After fail. of two previous tmts. and with no CNS involvem.
C/I: Hyperses, lact.
Proteasome Inhibitor. Carfilzomib 60 mg/vial. SINGLE USE VIALS (Pwdr. for sol. for
inject.): I.V. over 2 to 10 min., on Days 1,
2, 8, 9, 15, 16, foll. by a rest period from
Days 17 to 28. Ea. 28day period is 1 tmt
cycle. In Cycle 1, a dose is 20 mg/m².
Dose must be indiv. adjust. accord.
with med. cond. and param. Modify
dos. based on toxic.
Tmt. of pts. with multiple myeloma who
have receiv. at least 2 prior ther. incl.
bortezomib and an immunomodul. ag.
and have demonstr. dis. progress. on or
within 60 days of compl. the last ther.
Appr. is based on response rate. Clinical
benefit, such as impr. in surv./sympt., has
not been verified.
Anti-Parathyroid Agent. Cinacalcet 30, 60, 90 mg. F.C. TABS: 14, 28, 84 x 30 mg, 60 mg, 90
mg. With food/shortly aft. meal, whole
and not div. Adults only. Second.
hyperparathyroidism: Initial: 30 mg 1 x
dly. Titrate every 2-4 wks to max. 180
mg 1 x dly. PTH levels to be assessed at
least 12 hrs. aft. dos. See lit.
Parathyroid carcinoma and primary
hyperparathyroidism: Initial: 30 mg 2 x
dly. Titrate every 2-4 wks as foll:
Sequentially: 30 mg 2 x dly; 60 mg 2 x
dly; 90 mg 2 x dly and 90 mg 3-4 x dly
as req. to reduce serum calc. conc. to
below upper limit of normal. Max: 90
mg 4 x dly.
Tmt. second. hyperparathyroidism (HPT)
in end-stage ren. dis. (ESRD) on maint.
dialysis as part of ther. regimen incl.
phosphate binders and/or vit. D steroids
(as appropriate). Reduct. hypercalcem. in
parathyroid carcinoma and primary HPT
for whom parathyroidectomy would be
indicated based on serum calc. levels
(defin. by relev. treat. guide.), but in whom
parathyroidectomy is not clinic. approp. or
Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml. PREFILL SYRINGE (ready-to-use) 1 x 6
mg/0.06 ml. One 6 mg dose for ea.
chemother. cycle S.C. inject. approx.
24 hrs follow. cytotox. chemother.
Reduct. durat. neutropen., incidence of
febrile neutropen. in pts. treated with cytotox. chemother. for malignancy (with
the except. of chron. myeloid leukem. and
Colony Stimulating Factor. Filgrastim 30 MU/ml (0.3 mg/ml), 30 MU/0.5 ml (0.6 mg/ml), 48 MU/0.5 ml (0.96 mg/ml). VIALS (sol. for inj.): 5×30MU (0.3 mg/
PREF. SYR. (sol. for inj.): 5×30MU (0.6 mg/
ml), 1, 5×48MU (0.96 mg/ml). Dosage ajust. individ. accord. pt. med. condition.
Reduct. in the duration of neutropenia and
the incidence of febrile neutropenia in pts.
treated with established cytotoxic
chemother. for malign. (with the exception
of chronic myeloid leukaemia and
myelodysplastic syndr.) and for the reduct.
in the duration of neutropenia in pts.
undergoing myeloablative ther. followed
by bone marrow transplant., considered
to be at incr. risk of prolon. severe
neutropenia. The safety and efficacy of
Filgrastim are similar in adults and child.
receiving cytotoxic chemother. Indic. for
the mobilisation of peripheral blood
progenitor cells (PBPCs). In pts., children/
adults, with severe congen., cyclic or
idiopathic neutropenia with an ANC of
≤0.5 ×10^9/l, and a history of severe or
recurrent infec., long-term admin. of this
drug is indicated to increase neutrophil
counts and to reduce the incidence and
duration of infect.-related events.
C/I: Hypersens. Filgrastim should not be
diluted with saline sol. Diluted filgrastim
may be adsorbed to glass and plast.